Literature DB >> 23706984

A new approach to second-line therapy for urothelial cancer?

Guru Sonpavde1, Matthew D Galsky, Joaquim Bellmunt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23706984     DOI： 10.1016/S1470-2045(13)70175-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

Authors:  Andrea Necchi; Gregory R Pond; Patrizia Giannatempo; Giuseppe Di Lorenzo; Bernhard J Eigl; Jenn Locke; Sumanta K Pal; Neeraj Agarwal; Austin Poole; Ulka N Vaishampayan; Guenter Niegisch; Syed A Hussain; Parminder Singh; Joaquim Bellmunt; Guru Sonpavde
Journal:  Clin Genitourin Cancer       Date:  2014-09-23       Impact factor: 2.872

2.  Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.

Authors:  Jian-Zhou Cao; Wei Wu; Jin-Feng Pan; Hong-Wei Wang; Jun-Hui Jiang; Qi Ma
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 3.  Immunotherapy in genitourinary malignancies.

Authors:  Kathan Mehta; Keyur Patel; Rahul A Parikh
Journal:  J Hematol Oncol       Date:  2017-04-24       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.